Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 4/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23384522 | 0.82 | HTR7 (0.48) | HRH3KDM1ADAOMAOBHTR7 | |
| SCHEMBL29345065 | 0.81 | MEN1 (0.41) | HRH3KDM1ADAOMAOBKDM4E | |
| SCHEMBL23384265 | 0.81 | HRH3 (0.49) | HRH3KDM1ADAOMAOBHTR7 | |
| SCHEMBL25700799 | 0.79 | KDM4E (0.40) | KDM1AKDM4EMEN1KMT2ASIGMAR1 | |
| SCHEMBL23384009 | 0.79 | HTR7 (0.49) | HRH3KDM1ADAOMAOBHTR7 | |
| SCHEMBL732901 | 0.79 | DAO (0.47) | HRH3KDM1ADAOMAOBHTR7 | |
| SCHEMBL22358056 | 0.79 | SIGMAR1 (0.38) | HRH3HTR7KDM4EMEN1KMT2A | |
| SCHEMBL25861594 | 0.78 | HTR7 (0.32) | HRH3KDM1ADAOHTR7KDM4E | |
| SCHEMBL25567948 | 0.78 | SIGMAR1 (0.43) | HRH3KDM1ADAOMAOBHTR7 | |
| SCHEMBL27271191 | 0.78 | HRH3 (0.58) | HRH3DAOMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250063-A1 | PYRAZOLONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-10 | — | — | US | disclosed |
| US-10654832-B2 | 3-(benzoimidazol-2-YL)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190352279-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352279-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | HRH3 3135/4885KDM1A 4010/4885DAO 3290/4885 |
| US-10654832-B2 | 3-(benzoimidazol-2-YL)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | HRH3 3135/4885KDM1A 4010/4885DAO 3290/4885 |
| US-20230250063-A1 | PYRAZOLONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | FPR2, FPR1, FPR3 | HRH3 1018/4885KDM1A 4705/4885DAO 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.